IDH2 and acute myeloid leukemia: Enasidenib was proven to be well tolerated and safe as a single agent and capable of inducing responses in R/R IDH2-mutated AML patients in a phase I/II study, with an ORR of 40.3% and a median DOR of 5.8 months [217].